2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.03 Overall Survival after Treatment with First-Line Osimertinib for EGFR-Mutant Advanced NSCLC in the US

Pdf Summary

This study explored the real-world overall survival (rwOS) of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC) treated with first-line osimertinib in the US. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), showed promising results in clinical trials, including a median overall survival (OS) of 38.6 months reported in the FLAURA trial. However, translating these results to real-world scenarios is crucial to understand long-term outcomes more broadly.<br /><br />Data were sourced retrospectively from three major US oncology databases, covering patients diagnosed with EGFR-mutant NSCLC and treated with osimertinib from April 2018 to October 2022. The study found a median rwOS of 28.6 months, which is about 10 months shorter than that seen in the FLAURA trial. At the two-year mark, the rwOS was 58%, and at five years, it was as low as 18%, indicating less favorable outcomes compared to clinical trials.<br /><br />Demographic data showed that the majority of patients were over 65, with interesting subgroup characteristics like brain metastases and specific genetic mutations (TP53 and L858R). These factors were associated with poorer survival outcomes. Risk factors including age, ECOG performance status, and specific mutation types significantly influenced rwOS. Moreover, 95% of patients possessed at least one risk factor for poor survival outcomes, and 33% had two risk factors.<br /><br />Lower rwOS in real-world settings stresses the need for improved treatment options and personalized medicine approaches, considering the observed risk factors. Additionally, about one-third of patients did not receive second-line treatment, highlighting a gap in treatment continuation and potential areas for improvement in patient management.<br /><br />The study underscores the importance of adapting treatment plans that align with individual patient risk profiles to potentially improve survival outcomes in real-world settings.

Asset Subtitle

Joshua Sabari

Meta Tag

Speaker Joshua Sabari

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

real-world overall survival

EGFR-mutant NSCLC

osimertinib

FLAURA trial

US oncology databases

brain metastases

TP53 mutation

L858R mutation

personalized medicine

treatment continuation